SeaStar_SM_LogoCard.png
CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial
July 16, 2024 08:30 ET | SeaStar Medical Holding Corporation
Reimbursement expected to accelerate medical site activations and cover a portion of the Company’s NEUTRALIZE-AKI trial costs DENVER, July 16, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...
SeaStar_SM_LogoCard.png
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
March 12, 2024 08:30 ET | SeaStar Medical Holding Corporation
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device...
SeaStar_SM_LogoCard.png
SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
December 29, 2022 08:30 ET | SeaStar Medical Holding Corporation
Approximately 4,000 children in the U.S. with AKI require Continuous Kidney Replacement Therapy (CKRT) DENVER and MINNEAPOLIS , Dec. 29, 2022 (GLOBE NEWSWIRE) -- SeaStar Medical Holding...